X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs CADILA HEALTHCARE - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS CADILA HEALTHCARE J.B.CHEMICALS/
CADILA HEALTHCARE
 
P/E (TTM) x 14.0 23.3 59.9% View Chart
P/BV x 2.2 5.9 37.7% View Chart
Dividend Yield % 0.2 0.8 21.8%  

Financials

 J.B.CHEMICALS   CADILA HEALTHCARE
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
CADILA HEALTHCARE
Mar-17
J.B.CHEMICALS/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs318460 69.2%   
Low Rs200305 65.4%   
Sales per share (Unadj.) Rs148.092.1 160.7%  
Earnings per share (Unadj.) Rs19.114.8 128.8%  
Cash flow per share (Unadj.) Rs23.918.5 129.6%  
Dividends per share (Unadj.) Rs0.503.20 15.6%  
Dividend yield (eoy) %0.20.8 23.1%  
Book value per share (Unadj.) Rs128.968.0 189.7%  
Shares outstanding (eoy) m84.821,023.74 8.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.2 42.1%   
Avg P/E ratio x13.625.8 52.5%  
P/CF ratio (eoy) x10.820.7 52.2%  
Price / Book Value ratio x2.05.6 35.7%  
Dividend payout %2.621.6 12.1%   
Avg Mkt Cap Rs m21,951391,581 5.6%   
No. of employees `0002.716.9 16.2%   
Total wages/salary Rs m1,84115,002 12.3%   
Avg. sales/employee Rs Th4,590.95,594.5 82.1%   
Avg. wages/employee Rs Th673.4890.1 75.7%   
Avg. net profit/employee Rs Th592.1899.9 65.8%   
INCOME DATA
Net Sales Rs m12,55194,295 13.3%  
Other income Rs m5421,286 42.1%   
Total revenues Rs m13,09395,581 13.7%   
Gross profit Rs m2,05519,036 10.8%  
Depreciation Rs m4123,750 11.0%   
Interest Rs m96450 21.3%   
Profit before tax Rs m2,08816,122 13.0%   
Minority Interest Rs m0338 -0.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m4691,289 36.4%   
Profit after tax Rs m1,61915,168 10.7%  
Gross profit margin %16.420.2 81.1%  
Effective tax rate %22.58.0 281.0%   
Net profit margin %12.916.1 80.2%  
BALANCE SHEET DATA
Current assets Rs m7,77860,223 12.9%   
Current liabilities Rs m4,35853,058 8.2%   
Net working cap to sales %27.27.6 358.6%  
Current ratio x1.81.1 157.2%  
Inventory Days Days5570 78.3%  
Debtors Days Days8088 90.8%  
Net fixed assets Rs m5,71372,984 7.8%   
Share capital Rs m1701,024 16.6%   
"Free" reserves Rs m10,54768,576 15.4%   
Net worth Rs m10,93769,600 15.7%   
Long term debt Rs m024,684 0.0%   
Total assets Rs m15,574152,207 10.2%  
Interest coverage x22.836.8 62.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.80.6 130.1%   
Return on assets %11.010.3 107.3%  
Return on equity %14.821.8 67.9%  
Return on capital %20.017.9 111.3%  
Exports to sales %48.70-   
Imports to sales %7.10-   
Exports (fob) Rs m6,115NA-   
Imports (cif) Rs m889NA-   
Fx inflow Rs m6,16921,280 29.0%   
Fx outflow Rs m1,28510,874 11.8%   
Net fx Rs m4,88410,406 46.9%   
CASH FLOW
From Operations Rs m1,39713,495 10.3%  
From Investments Rs m-320-29,103 1.1%  
From Financial Activity Rs m-1,19623,158 -5.2%  
Net Cashflow Rs m-1027,556 -1.4%  

Share Holding

Indian Promoters % 55.4 74.8 74.1%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 8.3 40.8%  
FIIs % 3.9 5.9 66.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 11.0 336.4%  
Shareholders   30,437 44,069 69.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare J.B.CHEMICALS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Jun 15, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 8-QTR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS